Literature DB >> 26153987

Immuno-oncology moves beyond PD-1.

Cormac Sheridan.   

Abstract

Mesh:

Substances:

Year:  2015        PMID: 26153987     DOI: 10.1038/nbt0715-673

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  2 in total

1.  Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo.

Authors:  Julia Cuende; Stéphanie Liénart; Olivier Dedobbeleer; Bas van der Woning; Gitte De Boeck; Julie Stockis; Caroline Huygens; Didier Colau; Joan Somja; Philippe Delvenne; Muriel Hannon; Frédéric Baron; Laure Dumoutier; Jean-Christophe Renauld; Hans De Haard; Michael Saunders; Pierre G Coulie; Sophie Lucas
Journal:  Sci Transl Med       Date:  2015-04-22       Impact factor: 17.956

2.  Immune-checkpoint inhibitors march on, now in combinations.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2014-04       Impact factor: 54.908

  2 in total
  3 in total

1.  Industry 'road tests' new wave of immune checkpoints.

Authors:  Ken Garber
Journal:  Nat Biotechnol       Date:  2017-06-07       Impact factor: 54.908

2.  Cooperation of PD-1 and LAG-3 in the exhaustion of CD4+ and CD8+ T cells during bovine leukemia virus infection.

Authors:  Tomohiro Okagawa; Satoru Konnai; Asami Nishimori; Naoya Maekawa; Shinya Goto; Ryoyo Ikebuchi; Junko Kohara; Yasuhiko Suzuki; Shinji Yamada; Yukinari Kato; Shiro Murata; Kazuhiko Ohashi
Journal:  Vet Res       Date:  2018-06-19       Impact factor: 3.683

3.  R409K mutation prevents acid-induced aggregation of human IgG4.

Authors:  Hiroshi Namisaki; Seiji Saito; Keiko Hiraishi; Tomoko Haba; Yoshitaka Tanaka; Hideaki Yoshida; Shigeru Iida; Nobuaki Takahashi
Journal:  PLoS One       Date:  2020-03-17       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.